CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 187 enrolled
Drug / intervention
Lyrica (pregabalin) +1 moredrug
Likely dose
Lyrica (pregabalin) 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00351611
NCT00351611Phase 4Completed
CompareCT.gov

PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Jul 13, 2006·Updated Apr 13, 2021

In Brief

A Phase 4 clinical trial evaluating Lyrica (pregabalin) and placebo for Epilepsies, Partial. Completed, enrolled 187 participants across 150 sites in 9 countries.

Detailed Summary

Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will be performed prior to receiving the study treatment and at the end of the study to see if there are any changes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsies, Partial
CountriesBulgaria, Czechia, Hungary, India, Mexico, Poland, South Korea, Thailand, United States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 13, 2006
Enrollment StartJul 26, 2006
Primary CompletionFeb 4, 2020
TodayJul 2, 2026
Enrollment to primary: 13.5 yearsPosted 20.0 years ago

Interventions

Lyrica (pregabalin)drug

150 mg twice a day, oral administration

placebodrug

Twice a day, oral administration